Our real-world data show a higher rate of unreported germline BRCA1/2 pathogenic variants compared to myChoice® CDx test data from breast and ovarian tumours tested in the randomised, Phase 3 PARPi trials OlympiAD and SOLO2, where the missed rate was much lower at 0.7% and 1.7%, respectively [15,16]. The gene discussed is BRCA1; the disease is ovarian neoplasm.